In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Dutch research envisions homes made from fungus
In The Netherlands, researchers at Utrecht University have submitted a paper detailing the potential for homes to be made out of fungus.
The group evaluates...
Living, programmable robots raise ethics concerns
In Boston, researchers have created living, programmable organisms that could one day have widespread applications, including cleaning microplastics from the oceans.
Dubbed xenobots by their...
Itaconix and Nouryon terminate chelates deal
In the United Kingdom, Itaconix and chemical giant Nouryon have mutually agreed to terminate an agreement in which Nouryon exclusively distributes Itaconix’s biobased chelating...